Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sau Chi Betty Yan"'
Autor:
Philip J. Ebert, Gary L. Heady, Bruce W. Konicek, Melinda D. Willard, Stephanie L. Stout, Julie Stewart, David E. Timm, Yi Zeng, Victoria L. Peek, Suzane L. Um, Isabella H. Wulur, Beverly L. Falcon, Andrew Capen, Kelly M. Credille, Yong Wang, Jennifer R. Stephens, Sau-Chi Betty Yan, Richard A. Walgren, Bharvin K. R. Patel
Publikováno v:
Oncotarget
Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib inhibits neurotrophic receptor tyrosine kinases NTRK1/2/3 which are oncogenic drivers in tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d248b4902618ce5f3d208e81ce69d6
https://doi.org/10.18632/oncotarget.24488
https://doi.org/10.18632/oncotarget.24488
Autor:
Andrew J.H. Simpson, Sau Chi Betty Yan, Steven P. LaRosa, Jeffrey D. Helterbrand, Wipada Chaowagul, Charles J. Fisher, Nicholas J. White, Barbara G. Utterback, Steven M. Opal
Summary Background Acute septicemic melioidosis is associated with systemic release of endotoxin and the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, interleukin-1, and interleukin-6. Excessive release of these cytokines may lead to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99de0d3573b58a0dabcdf90997b4550a
https://ora.ox.ac.uk/objects/uuid:6d710803-3fba-4841-9991-34a698d0d655
https://ora.ox.ac.uk/objects/uuid:6d710803-3fba-4841-9991-34a698d0d655
Publikováno v:
The International Journal of Artificial Organs. 27:360-370
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46554a38cc5199607f8fbd53da26f596
https://doi.org/10.1177/039139880402700504
https://doi.org/10.1177/039139880402700504
Autor:
Jeffrey D. Helterbrand, William L. Macias, Mary E. Seger, Gerald Johnson, Jean‐Francois Dhainaut, Sau Chi Betty Yan, David S. Small
Publikováno v:
Clinical Pharmacology & Therapeutics. 72:391-402
Objective We aimed to characterize the pharmacokinetics and pharmacodynamics of drotrecogin alfa (activated) (recombinant human activated protein C) in patients with severe sepsis. Methods Patients (N = 1690) in a randomized, double-blind, placebo-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17122a91e3871d21781fbd9ccc4b1ca8
https://doi.org/10.1067/mcp.2002.128148
https://doi.org/10.1067/mcp.2002.128148
Autor:
Scott W. Eastman, Swee-Seong Wong, Michael Topper, Thompson N. Doman, David Schaer, Jason Manro, Amaladas Nelusha, Sau-Chi Betty Yan, Ruslan D. Novosiadly, Gerald Hall, Julie Stewart, Michael Kalos, Victoria L. Peek, Any T. Pappas, Bruce W. Konicek, Jennifer R. Stephens, Beverly L. Falcon, Philip W. Iversen, Richard A. Walgren, Um L. Um, Kelly M. Credille, Colleen A. Burns
Publikováno v:
Cancer Research. 77:5590-5590
The combination of tumor targeted therapeutics with PD-L1 checkpoint blockade is being explored as a method to increase the clinical benefits of immunotherapy, and expand response to additional cancer types. Merestinib (Mer) is a kinase inhibitor tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be254af902ace0bd3b087abf257fdef7
https://doi.org/10.1158/1538-7445.am2017-5590
https://doi.org/10.1158/1538-7445.am2017-5590
Autor:
Holly Kay Cannon, Suzane L. Um, Jessica A. Roseberry Baker, Ruslan D. Novosiadly, Volker Wacheck, Roger Agyei, Sudhakar Chintharlapalli, Joel D. Cook, Isabella H. Wulur, William John Feaver, Ling Liu, Jennifer R. Stephens, Lysiane Huber, Linda N. Lee, Robert Evans, Sau-Chi Betty Yan, Victoria L. Peek, Liandong Ma
Publikováno v:
Cancer Research. 77:519-519
Background: MET amplification (amp) is a resistance mechanism to EGFR TKI treatment. Emibetuzumab, a bivalent MET antibody (Ab) blocks HGF binding to MET and internalizes the receptor. Combination of emibetuzumab with EGFR TKIs (erlotinib, AZD9291, C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3be52eabcb80cc78e0196ad6d3709305
https://doi.org/10.1158/1538-7445.am2017-519
https://doi.org/10.1158/1538-7445.am2017-519
Autor:
Diane M. Bodenmiller, Julie Stewart, Sau-Chi Betty Yan, Anthony S. Fischl, Victoria L. Peek, Glenn F. Evans, Jennifer R. Stephens, Seema Iyer, Sudhakar Chintharlapalli, Xi Lin, Beverly L. Falcon
Publikováno v:
Cancer Research. 77:1823-1823
Merestinib (LY2801653) is an orally bioavailable small molecule inhibitor of several oncokinases, including MET, AXL, DDR1/2, MERTK, ROS1, Tie2 (aka TEK), and MKNK1/2. Merestinib has been extensively characterized in a wide range of preclinical tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88b083a0c77354d50ad7c2459ce74536
https://doi.org/10.1158/1538-7445.am2017-1823
https://doi.org/10.1158/1538-7445.am2017-1823
Autor:
Ling Liu, Jennifer R. Stephens, Volker Wacheck, Bruce W. Konicek, Victoria L. Peek, Richard A. Walgren, Suzane L. Um, Sau-Chi Betty Yan, Wei Zeng
Publikováno v:
Cancer Research. 77:528-528
Background: MET ex14 skipping, present in ~3% of lung cancer, is a strong oncogenic driver which is further evidenced by case reports of patients response to MET TKI treatment. ~15% of tumors in patients that harbor MET ex14 skipping also have MET am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec774d46ac6d633e148e7f4a64cabed2
https://doi.org/10.1158/1538-7445.am2017-528
https://doi.org/10.1158/1538-7445.am2017-528
Autor:
Sau-Chi Betty Yan, Kelly M. Credille, Suzane L. Um, John N. Calley, Victoria L. Peek, Jennifer R. Stephens, Andrew Capen, Yi Zeng, Philip J. Ebert, Steve M. Bray, Isabella H. Wulur, Melinda D. Willard, Richard A. Walgren, Bruce W. Konicek, Bharvin Kumar Patel, Gary L. Heady
Publikováno v:
Cancer Research. 76:2647-2647
In cancer, the formation of chimeric gene fusions by genomic rearrangement causes aberrant receptor tyrosine kinase activation resulting in sustained oncogenic signaling driving tumorigenesis. Neurotrophic tyrosine receptor kinase 1 (NTRK1), the cogn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebed1fedf723cd14ff6aefa642780ca
https://doi.org/10.1158/1538-7445.am2016-2647
https://doi.org/10.1158/1538-7445.am2016-2647